Britain and America have signed a significant commercial pact that will keep no duties on British drug products going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to increase spending on pharmaceuticals through the NHS. This pledge ensures that tariffs on these crucial products will be held at zero for a period of the next three years.
This agreement comes after recent statements to significantly raise tariffs on patented drug products, with increases mentioned up to double the cost.
"This arrangement between the United Kingdom strengthens the worldwide climate for new treatments and establishes long-overdue equity to U.S.–U.K. drug exports," a statement declared.
Commercial Significance
Medicines represent one of the Britain's most significant goods shipped to the United States, which is clearly the largest buyer for leading British pharmaceutical firms.
Export figures show that in the 12 months leading up to September, the UK exported medicines worth over eleven billion pounds to the US. This value made up nearly one-fifth of all goods exports in that span.
"This guarantee safeguards jobs, stimulates funding and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a government official stated.
Key UK Commitments
The pact entails several notable pledges from the UK:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new treatments to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to double total health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The percentage drug companies must refund to the NHS to prevent overspending will be limited at 15%. Last year, rebates were more than twenty percent.
Industry Background
This agreement follows a long-running row between the drug companies and the ministers over medicine costs and regulatory access.
The disagreement were heightened by arguments that American consumers were charged significantly more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been paused or scrapped, while major investments have been pledged toward US facilities.
The Science Minister stated that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had declined as a percentage of its total funding over the previous ten-year period.
